id: NEW:pulmonary_perfusion_defects_residual_vascular_obstruction_to_NEW:post_pulmonary_embolism_persistent_symptoms
name: Pulmonary Perfusion Defects or Residual Vascular Obstruction â†’ Post-Pulmonary Embolism Persistent
  Symptoms
from_node:
  node_id: NEW:pulmonary_perfusion_defects_residual_vascular_obstruction
  node_name: Pulmonary Perfusion Defects or Residual Vascular Obstruction
to_node:
  node_id: NEW:post_pulmonary_embolism_persistent_symptoms
  node_name: Post-Pulmonary Embolism Persistent Symptoms
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Acute pulmonary embolism causes occlusion of pulmonary vasculature'
- 'Step 2: Despite anticoagulant treatment, residual thrombus or organized fibrotic clots may persist
  in pulmonary vessels'
- 'Step 3: Persistent vascular obstruction leads to mismatched perfusion defects detectable on V/Q scan'
- 'Step 4: Impaired pulmonary blood flow contributes to chronic functional limitations including dyspnea
  and reduced exercise tolerance'
- 'Step 5: Patients experience post-PE syndrome manifestations including CTEPH, CTEPD, or post-PE functional
  impairment'
evidence:
  quality_rating: A
  n_studies: 12
  primary_citation: 'L. A. Cimini et al. 2024. "Pulmonary perfusion defects or residual vascular obstruction
    and persistent symptoms after pulmonary embolism: a systematic review and meta-analysis." https://doi.org/10.1183/23120541.01010-2023'
  supporting_citations:
  - Reference 1-4 in original paper describe up to 50% of acute PE survivors having persistent symptoms
    or alterations of cardiocirculatory function
  - Reference 5 defines post-PE syndrome criteria for patients symptomatic after 3 months of anticoagulation
  - Reference 6-10 describe various aetiologies of post-PE syndrome including CTEPH and CTEPD
  - Additional citations require full-text access
  doi: 10.1183/23120541.01010-2023
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Presence of pulmonary perfusion defects or residual vascular obstruction after acute pulmonary
  embolism is associated with a 2.15-fold increased odds of persistent symptoms during follow-up. Among
  patients with these defects, 48% remained symptomatic compared to 34% without such defects. However,
  the authors note that a significant proportion of patients with perfusion defects reported no limitations,
  indicating that direct causality remains unproven.
quantitative_effects:
  effect_size:
    value: 2.15
    type: odds_ratio
    ci_lower: 1.66
    ci_upper: 2.78
  sample_size: 1888
  heterogeneity_i_squared: 0.0
moderators:
- name: time_since_pulmonary_embolism
  direction: varies
  strength: moderate
  description: Follow-up ranged from 2-72 months (median 6 months), which may influence persistence of
    defects and symptoms
structural_competency:
  equity_implications: This mechanism is primarily biological rather than structural. However, healthcare
    access for adequate anticoagulation therapy, follow-up imaging (V/Q scan, CTPA), and specialist care
    for post-PE syndrome may vary by socioeconomic status, insurance coverage, and geographic location.
    Patients in healthcare deserts or those without specialist access may experience worse outcomes due
    to delayed diagnosis of CTEPH or CTEPD. The finding that causality is unproven suggests other factors
    (potentially including social determinants affecting recovery, rehabilitation access, and deconditioning)
    may contribute to persistent symptoms.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.358173'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
